BRCA-D - Clinical trial • Breast Cancer Foundation NZ


Updated: January 30, 2020

This is a proof-of-concept pilot study to determine if short-term treatment with denosumab (trade names Prolia and Xgeva) is a feasible chemoprevention option against breast cancer for BRCA1 and BRCA2 mutation carriers.

You may be eligible to join this study if you are a pre-menopausal woman aged between 18 years to 50 years and have documented BRCA1 or BRCA2 mutation considering prophylactic mastectomy, or are willing to undergo two breast biopsies on separate occasions.

For full trial information


The Royal Melbourne Hospital, Melbourne


Geoffrey Lindeman

If you think you might be a candidate for this trial, use the contact details supplied, or talk to your doctor.

Want to access a trial that's not in your area? It's not always possible, but if you're interested, email us at

Similar clinical trials

For Screening, prevention, familial and other

Are we out of date? If you have updated or new information about a trial, we’d be grateful if you’d share it with us – email your update to

Find clinical trials

Interested in a clinical trial?

Subscribe for updates & stay in the loop with new studies.